tiprankstipranks
Trending News
More News >
Novartis Ag (DE:NOTA)
FRANKFURT:NOTA
Germany Market
Advertisement

Novartis (NOTA) Earnings Dates, Call Summary & Reports

Compare
20 Followers

Earnings Data

Report Date
Feb 04, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
1.7
Last Year’s EPS
1.71
Same Quarter Last Year
Moderate Sell
Based on 3 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Oct 28, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a strong growth performance across key brands and successful pipeline advancements, despite challenges from generic erosion and market dynamics.
Company Guidance
In the Novartis Q3 2025 earnings call, the company reported a solid sales growth of 7% and a core operating income increase of 7%, maintaining a core margin at 39.3%. Significant pipeline milestones were achieved, including FDA approval for Rhapsido and positive Phase III results for several drugs like Ianalumab and Pluvicto. The priority brands, including Kisqali and Kesimpta, drove robust growth with a 35% increase, showcasing strong performances across various markets. Novartis reaffirmed its full-year guidance, expecting high single-digit growth in net sales and low-teens growth in core operating income despite generic headwinds. The company continues to focus on innovation and expansion, highlighted by their proposed acquisition of Avidity, aiming to bolster long-term growth prospects.
Solid Sales and Core Operating Income Growth
Novartis delivered a 7% increase in sales and core operating income, maintaining a core margin of 39.3%.
Strong Performance of Key Brands
Kisqali grew 68%, Kesimpta 44%, Pluvicto 45%, and Scemblix 95%, with robust growth across multiple markets.
FDA Approvals and Positive Pipeline Results
Important approvals include Rhapsido for CSU, with positive Phase III results for Ianalumab and Pluvicto, among others.
Free Cash Flow and Capital Allocation
Free cash flow reached $16 billion for the first nine months, enabling significant reinvestment and shareholder returns.
2025 Guidance Reaffirmed
The company expects high single-digit sales growth and low teens growth in core operating income for the full year.

Novartis (DE:NOTA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DE:NOTA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 04, 2026
2025 (Q4)
1.70 / -
1.712
Oct 28, 2025
2025 (Q3)
1.97 / 1.95
1.7819.22% (+0.16)
Jul 17, 2025
2025 (Q2)
2.03 / 2.09
1.70322.84% (+0.39)
Apr 29, 2025
2025 (Q1)
1.83 / 1.97
1.55626.67% (+0.42)
Jan 31, 2025
2024 (Q4)
1.56 / 1.71
1.32329.41% (+0.39)
Oct 29, 2024
2024 (Q3)
1.68 / 1.78
1.50418.39% (+0.28)
Jul 18, 2024
2024 (Q2)
1.60 / 1.70
1.49913.61% (+0.20)
Apr 23, 2024
2024 (Q1)
1.45 / 1.56
1.40211.04% (+0.15)
Jan 31, 2024
2023 (Q4)
1.43 / 1.32
1.2466.18% (+0.08)
Oct 24, 2023
2023 (Q3)
1.44 / 1.50
1.29516.15% (+0.21)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:NOTA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 28, 2025
€110.00€105.00-4.55%
Jul 17, 2025
€100.50€104.00+3.48%
Apr 29, 2025
€99.20€101.00+1.81%
Jan 31, 2025
€94.11€97.99+4.12%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Novartis Ag (DE:NOTA) report earnings?
Novartis Ag (DE:NOTA) is schdueled to report earning on Feb 04, 2026, TBA (Confirmed).
    What is Novartis Ag (DE:NOTA) earnings time?
    Novartis Ag (DE:NOTA) earnings time is at Feb 04, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Novartis Ag stock?
          The P/E ratio of Novartis is N/A.
            What is DE:NOTA EPS forecast?
            DE:NOTA EPS forecast for the fiscal quarter 2025 (Q4) is 1.7.

              Novartis (DE:NOTA) Earnings News

              NVS Earnings: Entresto Drugmaker Novartis Tops Estimates as Patent Expiry Looms
              Premium
              Market News
              NVS Earnings: Entresto Drugmaker Novartis Tops Estimates as Patent Expiry Looms
              9M ago
              NVS Earnings: Novartis Beats Q2 Estimates, Raises Profitability Outlook
              Premium
              Market News
              NVS Earnings: Novartis Beats Q2 Estimates, Raises Profitability Outlook
              1y ago
              NVS Earnings: Novartis Beats Q1 Estimates, Raises Outlook
              Premium
              Market News
              NVS Earnings: Novartis Beats Q1 Estimates, Raises Outlook
              2y ago
              Novartis (NYSE:NVS) Plummets on Q4 Miss
              Premium
              Market News
              Novartis (NYSE:NVS) Plummets on Q4 Miss
              2y ago
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis